Merdad Parsey -- Chief Medical Officer
Sure, Michael. Yes, couldn't agree more. Look, I think the conversation we'll have in the Type A meeting will center around really what level of evidence the FDA would be looking for on both of those issues, right, in terms of trying to get to a better benefit/risk understanding. And so that will depend -- so we need to find that out from the 200-milligram standpoint, and we need to find it out from the MANTA and MANTA-RAy standpoint.
So those two things we will get guidance from the FDA at the Type A meeting. And then based on that outcome, we will make some decisions how to go forward, whether there's a clear path, whether we have to only go forward in IBD or whether 200 milligrams is not viable until MANTA reads out, MANTA-RAy readout. All those are possibilities, so it's hard to speculate what the outcome of that will be. We'll be transparent obviously as we have that discussion with how we'll proceed.
Alethia Young -- Cantor Fitzgerald -- Analyst
Hey guys. Thanks for taking my question. I just wanted to talk a little bit about kind of big picture immunology. So maybe depending on what you decide with filgotinib next year based on some of the conversations, like how are you thinking about the space? Are you still committed? Would you consider doing M&A? Or do you have an internal pipeline that continue to drive potential revenues there?
Dan O'Day -- Chairman and Chief Executive Officer
Thanks, Alethia. I'll start and then maybe Merdad can add as well. But first of all, I mean nothing has changed about our dedication to our three disease areas. As you know, I mean our strategy that we announced at the beginning of the year was based upon two really strong scientific disciplines that we have from a discovery perspective at Gilead and with our partners, and that is antivirals and immunomodulation.
And we've been firmly focused on that strategy in terms of how it plays out in both antivirals, inflammation and fibrosis and then also oncology. So we think there's a lot of synergies associated with that science. Obviously, immunology, as you know, goes across so many disease states. Immunology plays in the antivirals, for instance, particularly when we look at some of our HBV cure programs.
But clearly, in the field of inflammation, we've already spoken about where we stand with filgotinib. We have a variety of follow-on agents within our Gilead research, with our partners with Galapagos, and we'll maintain an external view on opportunities to continue to advance our inflammation portfolio in-house. And you can see, of course, what we've done in the oncology field, predominantly immuno-oncology over the past year, really building up our oncology base based upon -- largely based upon immuno-oncology. Trodelvy allows us to have a really strong footprint now into solid tumors in a pan-tumor way, which we think will be very complementary to our first-in-class, best-in-class immuno-oncology portfolio.
Merdad, maybe you want to add as well your view on that question as well.
Merdad Parsey -- Chief Medical Officer
I think you hit all the key points, Dan. I think the only thing I'd add is I think we really have a great team here, and I think that team is going to be really great about charting our future in immunology. But as Dan said, we remain committed to that, and we'll continue to look at both near- and long-term opportunities there that makes sense for us in the portfolio.
Dan O'Day -- Chairman and Chief Executive Officer
I mean maybe, Merdad, it's just important to emphasize the unmet medical need in that area. It's still a very significant.
Merdad Parsey -- Chief Medical Officer
Yes. And maybe the only other thing I'd add is that we look at it through a fairly broad lens of what immunology means. There are a lot of indications with a lot of unmet need that persist in that space, and we'll be looking for that transformative profile.